首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1977130篇
  免费   143277篇
  国内免费   3983篇
耳鼻咽喉   28530篇
儿科学   65017篇
妇产科学   57593篇
基础医学   286197篇
口腔科学   55622篇
临床医学   168262篇
内科学   388892篇
皮肤病学   41792篇
神经病学   155177篇
特种医学   78001篇
外国民族医学   672篇
外科学   307810篇
综合类   42289篇
现状与发展   1篇
一般理论   528篇
预防医学   146114篇
眼科学   45720篇
药学   147553篇
  1篇
中国医学   3887篇
肿瘤学   104732篇
  2018年   18954篇
  2016年   16136篇
  2015年   18480篇
  2014年   26044篇
  2013年   39835篇
  2012年   54004篇
  2011年   57914篇
  2010年   34634篇
  2009年   32736篇
  2008年   55697篇
  2007年   59881篇
  2006年   60784篇
  2005年   59590篇
  2004年   57193篇
  2003年   55510篇
  2002年   54625篇
  2001年   88177篇
  2000年   90608篇
  1999年   77403篇
  1998年   21946篇
  1997年   19822篇
  1996年   19955篇
  1995年   18737篇
  1994年   17837篇
  1993年   16661篇
  1992年   61910篇
  1991年   60516篇
  1990年   59502篇
  1989年   57588篇
  1988年   53768篇
  1987年   52740篇
  1986年   50481篇
  1985年   48199篇
  1984年   36102篇
  1983年   31127篇
  1982年   18695篇
  1981年   16442篇
  1979年   34090篇
  1978年   23968篇
  1977年   20536篇
  1976年   19442篇
  1975年   21375篇
  1974年   25283篇
  1973年   24331篇
  1972年   23159篇
  1971年   21527篇
  1970年   20263篇
  1969年   19224篇
  1968年   18236篇
  1967年   16300篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets.  相似文献   
102.
103.
104.

Background

Arterial vascular anomalies in patients undergoing kidney transplantation (KT) are correlated with a higher incidence of early surgical complications, potentially causing graft loss. Arterial reconstruction allows patients to overcome these surgical challenges, thus minimizing the risk of poor outcomes. The aim of the present study is to retrospectively investigate the safety and effectiveness of the multiple arterial reconstruction technique with a Teflon patch in case of an unavailable aortic patch: to do so, surgical complications, graft function, and patient survival were evaluated.

Methods

During the period January 2009 to August 2016, 202 adult deceased-donor KTs were performed at our center. Group A (n = 27; reconstruction of multiple arteries) and Group B (n = 175; control group) were compared.

Results

No differences were observed between the 2 groups in terms of early postoperative course, with no vascular complication observed in Group A. No vascular patch infections were reported, nor longer cold ischemia time rates. Similarly, long-term survival rates were similar between the 2 groups.

Conclusions

The Teflon-patch arterial reconstruction technique appears to be safe and effective, with an acceptable balance of benefits and potential risks of using a prosthetic material. Studies based on larger series are needed to further validate this approach.  相似文献   
105.
106.
107.
108.
109.
BackgroundThe aim of this paper is to assess the current state of quality and outcomes measures being reported for hepatic resections in the recent literature.MethodsMedline and PubMed databases were searched for English language articles published between 1 January 2002 and 30 April 2013. Two examiners reviewed each article and relevant citations for appropriateness of inclusion, which excluded papers of liver donor hepatic resections, repeat hepatectomies or meta-analyses. Data were extracted and summarized by two examiners for analysis.ResultsFifty-five studies were identified with suitable reporting to assess peri-operative mortality in hepatic resections. In only 35% (19/55) of the studies was the follow-up time explicitly stated, and in 47% (26/55) of studies peri-operative mortality was limited to in-hospital or 30 days. The time period in which complications were captured was not explicitly stated in 19 out of 28 studies. The remaining studies only captured complications within 30 days of the index operation (8/28). There was a paucity of quality literature addressing truly patient-centred outcomes.ConclusionQuality outcomes after a hepatic resection are inconsistently reported in the literature. Quality outcome studies for a hepatectomy should report mortality and morbidity at a minimum of 90 days after surgery.  相似文献   
110.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号